Literature DB >> 3263215

Suppression of lymphocyte alloreactivity by early gestational human decidua. II. Characterization of the suppressor mechanisms.

P K Lala1, T G Kennedy, R S Parhar.   

Abstract

We have earlier shown that first trimester human decidual cells (typical decidual cells and decidual macrophages) suppress lymphocyte alloreactivity (MLR and CTL generation) in vitro in an MHC-unrestricted manner and that this suppression is mediated by PGE2. The present study explored the mechanisms underlying this suppression by noting the effects of decidual cells (+/- indomethacin or anti-PGE2 antibody) or chemically pure PGE2 on numerous T lymphocyte activation events following allogeneic stimulation in mixed lymphocyte culture (MLC) or polyclonal activation with Con A. The results revealed that this suppression was the net result of an action of PGE2 on at least two events during lymphocyte activation: (i) a down-regulation of IL-2 receptor development on lymphocytes, quantitated with a radioimmunoassay and radioautography; this was noted in MLC or Con A-stimulated lymphocyte cultures in the presence of decidual cells (reversible in the presence of indomethacin or anti-PGE2 antibody), or PGE2, but not PGF2 alpha; (ii) an inhibition of IL-2 production in the MLC, measured with a bioassay using an IL-2-dependent T cell line (CTLL-2) and a recombinant IL-2 standard. These effects blocked cell proliferation and eventual generation of killer cells in the MLC. Decidual cells or PGE2 did not interfere with IL-2-dependent proliferation of CTLL-2 cells, which require an interaction between IL-2 receptors on these cells and IL-2. Finally, neither agent interfered with the lytic function of CTL, once generated. These results indicate that the PGE2-mediated immunosuppressor function of early gestational human decidual cells is accomplished by an afferent blockade of the early events in T lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263215     DOI: 10.1016/0008-8749(88)90241-9

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Expression of activation antigens CD69, HLA-DR, interleukin-2 receptor-alpha (IL-2R alpha) and IL-2R beta on T cells of human decidua at an early stage of pregnancy.

Authors:  S Saito; K Nishikawa; T Morii; N Narita; M Enomoto; M Ichijo
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

Review 2.  Regulation of immune responses by prostaglandin E2.

Authors:  Pawel Kalinski
Journal:  J Immunol       Date:  2012-01-01       Impact factor: 5.422

3.  Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.

Authors:  A Eisenthal
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2.

Authors:  N K Khoo; F P Chan; M N Saarloos; P K Lala
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

5.  Placentally derived prostaglandin E2 acts via the EP4 receptor to inhibit IL-2-dependent proliferation of CTLL-2 T cells.

Authors:  N Kvirkvelia; I Vojnovic; T D Warner; V Athie-Morales; P Free; N Rayment; B M Chain; T W Rademacher; T Lund; I M Roitt; P J Delves
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

6.  Isolation of Primary Human Decidual Cells from the Fetal Membranes of Term Placentae.

Authors:  Tali Farine; Michael Parsons; Stephen Lye; Oksana Shynlova
Journal:  J Vis Exp       Date:  2018-04-30       Impact factor: 1.355

7.  Effects of histamine type-2 receptor antagonists on indomethacin and IL-2 immunotherapy of metastasis.

Authors:  M N Saarloos; N K Khoo; P K Lala
Journal:  Clin Exp Metastasis       Date:  1993-05       Impact factor: 5.150

8.  Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses.

Authors:  Yao Ye; Aurelia Vattai; Nina Ditsch; Christina Kuhn; Martina Rahmeh; Sven Mahner; Myriam Ripphahn; Roland Immler; Markus Sperandio; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Endocr Connect       Date:  2018-04-26       Impact factor: 3.335

9.  Manifestations of immune tolerance in the human female reproductive tract.

Authors:  Gary F Clark; Danny J Schust
Journal:  Front Immunol       Date:  2013-02-13       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.